TABLE 3.
Univariate analysis: Summary of effects of different covariates on time to CLAD.
| Summary of effects of different covariates on time to CLAD (n = 182) | |||
|---|---|---|---|
| Hazard ratio | p-value | ||
| Demographics | Male | 1.22 (0.81–1.82) | 0.342 |
| Age | 1.01 (0.99–1.02) | 0.338 | |
| Body mass index | 1.02 (0.98–1.06) | 0.315 | |
| Surgical Procedure | |||
| BSLTx | 0.88 (0.52–1.51) | 0.653 | |
| SLTx | 1.05 (0.56–1.96) | 0.880 | |
| Diagnosis | Cystic Fibrosis | 0.52 (0.30–0.90) | 0.019 |
| Chronic obstructive pulmonary disease | 1.46 (0.98–2.17) | 0.060 | |
| Interstitial lung disease | 1.03 (0.64–1.65) | 0.902 | |
| Pulmonary hypertension | 1.08 (0.52–2.22) | 0.838 | |
| Re-Transplant | 1.27 (0.22–7.45) | 0.789 | |
| Other | 1.01 (0.25–4.13) | 0.991 | |
| EVE | Use as an Immunosuppressant | 1.27 (0.87–1.86) | 0.208 |
| Time of Transplant to Initiation | 1.00 (1.00–1.00) | 0.446 | |
| Discontinuation of EVE | 1.46 (0.84–2.53) | 0.178 | |
| EVE Level | 1.03 (0.91–1.16) | 0.677 | |
| Immunosuppression a | Tacrolimus | 0.86 (0.51–1.46) | 0.580 |
| Ciclosporin | 1.08 (0.61–1.92) | 0.782 | |
| Azathioprine | 0.99 (0.68–1.45) | 0.974 | |
| Mycophenolate | 0.76 (0.51–1.13) | 0.175 | |
| Tacrolimus Level | 1.04 (0.97–1.11) | 0.319 | |
| Ciclosporin Level | 1.00 (1.00–1.00) | 0.725 | |
| Indication | Renal preservation | 1.98 (1.09–3.59) | 0.024 |
| CLAD | Azithromycin prophylaxis | 1.22 (0.66–2.27) | 0.522 |
| Spirometry | FEV1: Time of starting EVE (measured) | 0.67 (0.53–0.86) | 0.001 |
| FEV1: Time of starting EVE (percentage) | 0.98 (0.97–0.99) | 0.003 | |
| FVC: Time of starting EVE (measured) | 0.84 (0.69–1.01) | 0.064 | |
| FVC: Time of starting EVE (measured) | 0.99 (0.98–1.00) | 0.012 | |
| FEV1: 1-year post starting EVE (measured) | 0.57 (0.44–0.73) | <0.0001 | |
| FEV1: 1-year post starting EVE (percentage) | 0.97 (0.97–0.98) | <0.0001 | |
| FVC: 1-year post starting EVE (measured) | 0.67 (0.54–0.83) | 0.0003 | |
| FVC: 1-year post EVE starting (percentage) | 0.97 (0.96–0.98) | <0.0001 | |
| Cytomegalovirus | Cytomegalovirus Reactivation b | 1.28 (0.86–1.92) | 0.220 |
Abbreviations: BSLTx, bilateral sequential lung transplant; CLAD, chronic lung allograft dysfunction; EVE, everolimus; FER, forced expiratory ratio; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SLTx, single lung transplant.
a
Maintenance immunosuppression at time of starting EVE.
b
Cytomegalovirus reactivation post starting EVE.